Previous 10 | Next 10 |
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) and healthy aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners 2024 Investor ...
2024-01-23 19:28:50 ET Summary Nutraceuticals and supplements industry is gaining traction due to increasing demand for products that promote well-being. ChromaDex Corporation offers an interesting technology and product, Niagen, which boosts NAD+ levels in the body. ChromaDex...
Tru Niagen is now available to US troops through an exclusive Military program ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) and healthy aging research, is proud to announce its inaugural initiative to support the US Military. ...
Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+ PR Newswire Qualia NAD+, Featuring ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen, Well Positioned To Become Category Leader In NAD+ Supplementation. ...
Building on a growing body of research showcasing NR as a potential therapeutic strategy for PD, this is the first clinical study to showcase the safety, tolerability, and beneficial metabolic effects of high-dose NR at 3,000 mg per day ChromaDex Corp. (NASDAQ:CDXC), a global author...
This is the longest Niagen NR clinical trial to date spanning two years and showcases that long-term Niagen NR is safe and well tolerated ChromaDex Corp. (NASDAQ:CDXC), one of the global authorities on Nicotinamide Adenine Dinucleotide (NAD + ) and healthy aging research, shares...
ChromaDex Corporation (NASDAQ: CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor p...
2023-11-08 21:02:16 ET ChromaDex Corporation (CDXC) Q3 2023 Earnings Conference Call November 8, 2023, 04:30 PM ET Company Participants Kendall Knysch - Director, Media Relations Rob Fried - CEO Brianna Gerber - CFO Conference Call Participants Ram Se...
2023-11-08 16:04:14 ET More on ChromaDex ChromaDex Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on ChromaDex Historical earnings data for ChromaDex Financial information for ChromaDex For further details see: ChromaDex GAAP EPS of ...
Total net sales of $19.5 million, a gross margin of 61.4% and a net loss of $1.0 million while achieving a positive Adjusted EBITDA of $0.5 million and positive operating cash flows for the three months ended September 30, 2023. ChromaDex Corp. (NASDAQ: CDXC) today announced financial r...
News, Short Squeeze, Breakout and More Instantly...
ChromaDex Corporation Company Name:
CDXC Stock Symbol:
NASDAQ Market:
ChromaDex Corporation Website:
U.S. FDA-registered 503B outsourcing facility, Wells Pharma of Houston, will compound and distribute Niagen (nicotinamide riboside chloride) IV and injections to Cenegenics, Clean Market/NutriDrip, Drip Hydration, EXTEN IV, Kensho Wellbeing, The NAD MD, Next Health, The Remedy Room, Restore Hyper...
ChromaDex continues to drive innovation and growth with its proprietary Tru Niagen ® supplement, backed by strong financial performance and a robust intellectual property portfolio ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD +...
NR improved the six-minute walking distance and treadmill walking time for those with PAD ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) research, shares results from a milestone phase II clinical study showcasing the promising effe...